PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma/Mycosis Fungoides Clinical Trial

Official title:
Phase 2a Study of Systemic PK and Serial ECG Determinations Following 8 Weeks of HyBryte Treatment

Status Completed

Clinical Trial Summary

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Peripheral
Mycoses
Mycosis Fungoides

Clinical Trial Details

NCT number	NCT05380635
Study type	Interventional
Source	Soligenix
Contact
Status	Completed
Phase	Phase 2
Start date	May 9, 2022
Completion date	August 16, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03837457` - PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study	Phase 2
Recruiting	`NCT06436677` - A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Completed	`NCT04702503` - Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL)	Phase 1
Not yet recruiting	`NCT06113081` - Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Recruiting	`NCT06149247` - HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL	Phase 2
Terminated	`NCT03713320` - SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides	Phase 2